- Home
- NBBK vs SLN Comparison
NBBK vs SLN Comparison
Compare NBBK & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBBK | SLN |
|---|---|---|
| Founded | 1892 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 926.5M | 678.0M |
| IPO Year | 2023 | 2010 |
Fundamental Metrics
Financial Performance| Metric | NBBK | SLN |
|---|---|---|
| Price | $22.73 | $12.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $23.50 | ★ $42.60 |
| AVG Volume (30 Days) | 225.3K | ★ 680.4K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | ★ 25.23 | N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | N/A | ★ $559,000.00 |
| Revenue This Year | $45.15 | N/A |
| Revenue Next Year | $4.18 | N/A |
| P/E Ratio | $25.31 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.84 | $4.19 |
| 52 Week High | $23.47 | $17.58 |
Technical Indicators
Market Signals| Indicator | NBBK | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 52.73 | 40.41 |
| Support Level | $22.28 | $4.70 |
| Resistance Level | $23.47 | $15.28 |
| Average True Range (ATR) | 0.45 | 0.74 |
| MACD | -0.02 | -0.28 |
| Stochastic Oscillator | 58.66 | 4.92 |
Price Performance
Historical ComparisonAbout NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. The group's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, consumer loans, and other related services.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.